Author:
Baraniuk James N,Jamieson Mary J
Publisher
Springer Science and Business Media LLC
Subject
Pulmonary and Respiratory Medicine,Immunology,Immunology and Allergy
Reference51 articles.
1. Mest HJ, Mentlein R: Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia. 2005, 48: 616-620. 10.1007/s00125-005-1707-5.
2. Anon: Januvia (sitagliptin) tablets. Circular Number. 9762802, Merck & Co., Inc. Whitehouse Station, NJ 088893
3. Göke B, Hershon K, Kerr D, Calle Pascual A, Schweizer A, Foley J, Shao Q, Dejager S: Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Horm Metab Res. 2008, 40 (12): 892-5. 10.1055/s-0028-1082334.
4. Anon: Onglyza (saxagliptin) tablets. Circular Number 1256316. 2009, Bristol-Meyers Squibb, Princeton, NJ 08543
5. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C: Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag. 2008, 4 (4): 753-68.
Cited by
31 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献